UBIMOTIF is a joint training and research program with focus on identification, characterization and exploitation of short linear motifs in the ubiquitin system. The consortium includes 13 research groups and 6 partners from 10 European countries.
UBIMOTIF is funded by Marie Sklodowska-Curie Innovative Training Networks (MSC-ITN) under the European Commission's Horizon 2020 programme, grant agreement 860517. The project started officially on 1 December 2019 and will run for four years.
https://ubimotif.ku.dk/
Train 15 highly skilled researchers ideally suited to support a European knowledge based economy.
Create strong long lasting links between relevant academic and industrial partners that will position European science and industry at the forefront of SLiM and ubiquitin research.
Explore novel therapeutic possibilities within the ubiquitin system that can contribute to the pipelines of European companies.
Petra Beli, Institute of Molecular Biology in Mainz, Germany
Helena Danielson, Beactica AB, Sweden
Norman Davey, Institute of Cancer Research, UK
Stefano Gianni, University of Rome La Sapienza, Italy
Ylva Ivarsson, Uppsala University, Sweden
Anton Khmelinskii, Institute of Molecular Biology in Mainz, Germany
Yogesh Kulathu, University of Dundee, UK
Reet Kurg, University of Tartu, Estonia
Niels Mailand, University of Copenhagen Denmark
Jakob Nilsson, University of Copenhagen, Denmark
Anders Bach, University of Copenhagen, Denmark
Matthias Peter, ETH Zürich, Switzerland
Ora Schueler-Furman, The Hebrew University of Jerusalem, Israel
Markus Queisser, GlaxoSmithKline, UK
Carlos Fontes, NZYTech Ltd, Portugal
Farid El Oualid, UbiQ BIO BV, The Netherlands
Stephan Pritz, BIOSYNTAN GmbH, Germany
Erik Jurgons, Intavis, Germany
Sašo Kocevar, hfp Consulting, Germany
Helen Walden, University of Glasgow, UK
Katrin Rittinger, Francis Crick Institute, UK
Toby Gibson, EMBL, Heidelberg Germany
Ari Helenius, Emeritus Professor ETH Zurich, Switzerland
